Get the Stockscreener App
14.92
0.53%
-0.08
Liquidia Corp stock is traded at $14.92, with a volume of 1.84M.
It is down -0.53% in the last 24 hours and up +10.44% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
See More
Previous Close:
$15.00
Open:
$14.95
24h Volume:
1.84M
Relative Volume:
1.34
Market Cap:
$1.28B
Revenue:
$17.49M
Net Income/Loss:
$-78.50M
P/E Ratio:
-12.43
EPS:
-1.2
Net Cash Flow:
$-52.85M
1W Performance:
-2.80%
1M Performance:
+10.44%
6M Performance:
+29.18%
1Y Performance:
+16.02%
1-Day Range:
$14.50
$15.18
1-Week Range:
$13.94
$16.05
52-Week Range:
$8.26
$19.41
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
14.92 | 1.31B | 17.49M | -78.50M | -52.85M | -1.20 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Downgrade | Oppenheimer | Perform → Underperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - mx.advfn.com
Liquidia Told to Swap Two Defenses Ahead of Trial on UTC Patent - Bloomberg Law News
Wells Fargo lifts Liquidia stock price target to $23 from $20 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod By Investing.com - Investing.com South Africa
Scotiabank Raises Price Target for Liquidia (LQDA) to $37.00 | LQDA Stock News - GuruFocus
These Analysts Boost Their Forecasts On Liquidia - Benzinga
Scotiabank Increases Price Target for Liquidia (LQDA) After Yutrepia Approval | LQDA Stock News - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analy - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analyst | LQDA Stock News - GuruFocus
Liquidia Technologies stock target raised to $33 at Raymond James - Investing.com
Breaking Down Liquidia: 12 Analysts Share Their Views - Benzinga
Liquidia (LQDA) Price Target Raised to $35 by HC Wainwright | LQ - GuruFocus
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQ - GuruFocus
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch By Investing.com - Investing.com South Africa
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQDA Stock News - GuruFocus
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference - The Globe and Mail
Liquidia (LQDA) Gains FDA Approval, Price Target Raised to $23 | - GuruFocus
Liquidia (LQDA) Gains FDA Approval, Price Target Raised to $23 | LQDA Stock News - GuruFocus
Needham Reiterates Buy Rating on LQDA with a Price Target of $25 - GuruFocus
Wells Fargo lifts Liquidia stock price target to $23 from $20 - Investing.com
BTIG raises Liquidia stock price target to $37, maintains buy - Investing.com
Liquidia (LQDA) Sees Price Target Boost After FDA Approval | LQD - GuruFocus
Liquidia (LQDA) Sees Price Target Boost After FDA Approval | LQDA Stock News - GuruFocus
Jefferies raises Liquidia Technologies stock target to $31 - Investing.com
Jefferies Boosts Liquidia (LQDA) Price Target After FDA Approval - GuruFocus
Jefferies Boosts Liquidia (LQDA) Price Target After FDA Approval | LQDA Stock News - GuruFocus
Jefferies Lifts Liquidia Technologies' Price Target to $31 From $27, Buy Rating Kept - marketscreener.com
Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga
Transcript : Liquidia CorporationSpecial Call - marketscreener.com
BTIG maintains Liquidia stock Buy rating, $29 target - Investing.com
Raymond James maintains Strong Buy on Liquidia stock, $29 target - Investing.com
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod - MSN
Liquidia Retail Buzz Surges After BofA Raises Price Target to $25 On Yutrepia FDA Nod By Stocktwits - Investing.com India
Liquidia (LQDA) Price Target Boosted to $25 by BofA | LQDA Stock News - GuruFocus
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey
FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus
Liquidia (LQDA) Trading Resumes After Brief Halt | LQDA Stock Ne - GuruFocus
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension - marketscreener.com
Liquidia (LQDA) Trading Resumes After Brief Halt | LQDA Stock News - GuruFocus
FDA Greenlights Liquidia's (LQDA) Yutrepia for Pulmonary Hyperte - GuruFocus
U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - The Manila Times
Trading Halted for Liquidia (LQDA) as Anticipated News Awaits | - GuruFocus
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - Yahoo Finance
Trading Halted for Liquidia (LQDA) as Anticipated News Awaits | LQDA Stock News - GuruFocus
Scotiabank maintains Liquidia stock with $36 target - Investing.com
Needham maintains Buy on Liquidia stock with $25 target - Investing.com
LQDA Stock Rating Reiterated by Needham with a $25 Price Target - GuruFocus
Raymond James maintains strong buy on Liquidia stock, $29 target - Investing.com
BTIG maintains buy on Liquidia with $29 target amid new data - Investing.com
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Liquidia Corp Stock (LQDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saggar Rajeev | Chief Medical Officer |
Apr 21 '25 |
Sale |
13.67 |
2,450 |
33,492 |
263,152 |
| Schundler Russell | General Counsel |
Apr 14 '25 |
Sale |
13.57 |
5,964 |
80,931 |
570,301 |
| JEFFS ROGER | Chief Executive Officer |
Apr 14 '25 |
Sale |
13.57 |
14,130 |
191,744 |
1,006,420 |
| Moomaw Scott | Chief Commercial Officer |
Apr 15 '25 |
Sale |
13.57 |
3,406 |
46,219 |
214,744 |
| Kaseta Michael | CFO and COO |
Apr 14 '25 |
Sale |
13.57 |
8,283 |
112,400 |
396,315 |
| Saggar Rajeev | Chief Medical Officer |
Apr 14 '25 |
Sale |
13.57 |
3,714 |
50,399 |
265,602 |
| Adair Jason | Chief Business Officer |
Apr 14 '25 |
Sale |
13.57 |
1,856 |
25,186 |
184,304 |
| Schundler Russell | General Counsel |
Mar 03 '25 |
Sale |
15.45 |
930 |
14,368 |
576,265 |
| Moomaw Scott | Chief Commercial Officer |
Mar 03 '25 |
Sale |
15.45 |
592 |
9,146 |
218,150 |
| Kaseta Michael | CFO and COO |
Mar 03 '25 |
Sale |
15.45 |
874 |
13,503 |
404,598 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):